CoronaryAtlas logo
CoronaryAtlas
D-dimer
Pathway / Coagulation & thrombus formation

D-dimer

protein

D-dimer indicates active coagulation and thrombus formation during acute coronary events.

Pathway placement
Cascade stepCoagulation & thrombus formation
Confidencehigh
RationaleAnchor molecule; fibrin turnover and thrombus formation marker in AMI.
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresNon-Type-I-associated
R — rupture / Type-I
—
C — non-Type-I
63
A — assay feasibility
96
E — evidence strength
63
T1DI (composite)
12
Specificity differential (R−C)-60.3
Direct evidence: higher in non-Type I (D=-1)
Low D-dimer associated with T1MI incidence vs T2MI (OR 0.87, 95% CI 0.77-0.98, P=0.027), i.e. D-dimer higher in T2MI
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 3
2anemia / acute blood lossmag 2
2hypovolemia / dehydrationmag 1
2tachyarrhythmiamag 2
2hypoxemia / respiratory failuremag 2
2hypertensive emergencymag 1
2high-demand / peri-operative stressmag 3
3sudden cardiac deathmag 1
4aPCI-related periproceduraln/a
4bstent thrombosisn/a
4cin-stent restenosismag 2
5CABG-relatedmag 2
Coverage: 10/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 28 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Platelet-poor plasma
Collection tube
Sodium citrate 3.2% (light blue-top)
Method / principle
Immunoturbidimetric (latex) or ELISA; POC immunofiltration
Reagent / substrate
Monoclonal anti-D-dimer (neoepitope) antibody-latex
Platform
Coagulation analyzer; POC
Turnaround · availability
STAT · FDA-cleared

Literature evidence(60)

Showing 40 of 60 linked references.

Clinical trials(1)